|
By Thursday, a small pox vaccine produced by Acambis PLC will be reviewed by a panel set up by the Food and Drug Administration. The Acambis small pox vaccine is rated as a second-generation vaccine which is manufactured by applying the cell-culture lines. The vaccine is a derivative of an older vaccine called Dryvax, made by Wyeth.
The manufacturer of the vaccine claims to be awaiting the endorsement of the FDA before sourcing for funds from the government via grants. The vaccine which is also called ACAM2000 would not be sold commercially in the United States since the routine vaccination of children in the US stopped in 1972.
Skin rash is one of the results of the virus and it could be severe and deadly in some cases, say 30% of the entire cases.
According to the FDA, safety measures with small pox vaccines like ACAM2000 and Dryvax is of utmost concern. There some side effects accompanying the vaccines and they comprise of seldom cases of inflammation of the heart-wall muscle known as myopericarditis and severe skin infections. A Report from clinical research says Acambis vaccine has no fatalities.
The agency carrying out the studies reached an observation that one of the studies involving the vaccines suggested the rate of myopericarditis is higher than previously suspected. Ten cases of myopericarditis were seen in the studies and manifested in both vaccines.
The FDA concluded that, ‘‘However, the potential benefits of administration of ACAM2000 during a smallpox outbreak to persons who are determined to be at high risk of exposure or who have been recently exposed outweigh potential risks.’’
Tags:
Click to add your tags...,
| Comments () >> |
 |
| Write comment |
You must be logged in to a comment. Please register if you do not have an account yet. |
 |
Contact
